Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
This is the same mechanism the body uses naturally during fasting, exercise or stress, AOD-9604 simply amplifies the signal
To find the dose per unit, we divide the total mcg by the total units: 5,000 mcg / 200 units = 25 mcg per unit
They have 3 key ingredients that work to promote the bodys innate pathway of fat reduction
374 Exendin-4 has also been shown to stimulate osteoblast activity and mitigate bone loss in an ovariectomized mouse model
Genes Genomes Genet